Gilead的塞拉德尔帕(Seladelpar)在治疗欧洲罕见肝病方面得到了积极的评价。 Gilead's Seladelpar gets positive review for treating rare liver disease in Europe.

欧洲医药机构人类医疗用产品委员会(CHMP)对Gilead Science的药物Seladelpar(Seladelpar)给予了积极评价,认为该药物治疗罕见的肝病,即初生血清炎。 Gilead Sciences has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug Seladelpar to treat Primary Biliary Cholangitis, a rare liver disease. 这一步骤使该药物更接近于在欧盟对几乎没有治疗选择的病人的潜在批准。 This step brings the drug closer to potential approval in the EU for patients who have few treatment options.